The Pharmacology Center

Filter Your Results




Study Evaluates Safety and Efficacy of DAPT After Complex PCI

October 17, 2016 -- An investigation of the safety and efficacy of long-term (≥ 12 months) versus short-term (3 or 6 months) dual-antiplatelet therapy (DAPT) with aspi…

Amgen’s Cholesterol-Lowering Repatha Meets Endpoints in GLAGOV IVUS Imaging Study

September 27, 2016 -- Amgen announced last week that the phase 3 GLAGOV trial evaluating the effect of the company’s Repatha (evolocumab) medication on coronary artery d…

FDA Approves Bolus Vial Format for Medicure’s Aggrastat

September 1, 2016 -- Medicure Inc. announced that it has received approval from the US Food and Drug Administration (FDA) for its new "bolus vial" product format for…

GLORIA-AF Registry Studies Boehringer Ingelheim’s Pradaxa in NVAF Patients in Routine Clinical Care

August 29, 2016 -- Boehringer Ingelheim Pharmaceuticals, Inc. announced that first outcome results from the GLORIA-AF registry show that treatment with the company’s Pra…

PRODIGY Analysis Shows Men and Women Have Similar Outcomes in DAPT Duration

August 22, 2016 -- A prespecified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study) trial was conducted …

One-Year Outcomes With Intracoronary Abciximab Evaluated in Diabetic Patients Undergoing Primary PCI

August 16, 2016 -- In diabetic patients with ST-segment elevation myocardial infarction (STEMI), the administration of intracoronary abciximab -- compared with the intravenous…

RE-VECTO Global Program Will Capture Clinical Practice Data on Boehringer Ingelheim’s Praxbind

August 15, 2016 -- Boehringer Ingelheim Pharmaceuticals, Inc. announced the initiation of its global RE-VECTO program, which will capture data on Praxbind (idarucizu…

Empagliflozin Supported by FDA Advisory Committee With 12-11 Vote

June 30, 2016 -- Boehringer Ingelheim and Eli Lilly and Company announced this week that the US Food and Drug Administration (FDA) Advisory Committee voted 12 -- 11 that subst…



2018 Buyer’s Guide

This Buyer’s Guide offers a searchable, comprehensive listing of the FDA-approved interventional devices available in the United States.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.